Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: Results from 101 centers

Transplantation

Volumn 99, Issue 2, 2015, Pages 400-404

  Opelz, Gerhard ^a   Morath, Christian ^a   Süsal, Caner ^a   Tran, Thuong Hien ^a   Zeier, Martin ^a   Döhler, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; BIOLOGICAL MARKER; BLOOD GROUP ABO SYSTEM;

ADULT; ANTIBODY REDUCTION; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; BLOOD GROUP ABO INCOMPATIBILITY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH CENSORED GRAFT SURVIVAL; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MYCOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SURVIVAL; PLASMAPHERESIS; SPLENECTOMY; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; VIRUS INFECTION; YOUNG ADULT; ADOLESCENT; ADVERSE EFFECTS; BLOOD; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INFANT; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; NEWBORN; PRESCHOOL CHILD; PROCEDURES; REGISTER; RISK FACTOR; TIME; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD GROUP INCOMPATIBILITY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; INFANT, NEWBORN; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PLASMA EXCHANGE; REGISTRIES; RISK FACTORS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923010784     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000312     Document Type: Article

References (19)

1. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955;34:327.
2. Murray JE,Merrill JP, Dammin GJ, et al. Study on transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery 1960;48:272.
3. Starzl TE, Marchioro TL, Holmes JH, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964;55:195.
4. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966;2:662.
5. Slapak M, Naik RB, Lee HA. Renal transplant in a patient with major donor-recipient blood group incompatibility: reversal of acute rejection by the use of modified plasmapheresis. Transplantation 1981;31:4.
6. Alexandre GP, Squifflet JP, De Bruyère M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987;19:4538.
7. Takahashi K, Saito K. ABO-incompatible kidney transplantation. Transplant Rev (Orlando) 2013;27:1.
8. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003;75:971.
9. Tydén G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003;76:730.
10. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005;5:145.
11. Tydén G, Donauer J, Wadström J, et al. Implementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation 2007;83:1153.
12. Morath C, Becker LE, Leo A, et al. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 2012;93:827.
13. Montgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012;93:603.
14. Barnett AN, Manook M, Nagendran M, et al. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation. Transpl Int 2014;27:187.
15. Genberg H, Kumlien G,Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008;85:1745.
16. Wilpert J, Fischer KG, Pisarski P, et al. Long-term outcome of ABOincompatible living donor kidney transplantation based on antigenspecific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010;25:3778.
17. Habicht A, Bröker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients - a single centre experience. Nephrol Dial Transplant 2011;26:4124.
18. Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012;7:1320.
19. Kahwaji J, Sinha A, Toyoda M, et al. Infectious complications in kidneytransplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011;6:2894.